Scribe Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1150 Marina Village Pkwy, Alameda, Calif...Phone Number
(510) 626-8587Website
www.scribetx.comRevenue
$51.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
3
1
1
1
About Scribe Therapeutics
Scribe Therapeutics is focused on revolutionizing medicine through the development of CRISPR-based therapeutics aimed at transforming individuals' lifetime risk for diseases. Their innovative approach emphasizes preventative and accessible genetic medicine, targeting prevalent health issues such as cardiometabolic diseases. The company collaborates with leading pharmaceutical partners to broaden its molecular engineering efforts across various therapeutic areas. Scribe Therapeutics envisions a future where genetic predispositions do not dictate health outcomes, empowering everyone to take control of their health destiny.Explore more
Scribe Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Scribe Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Scribe Therapeutics is spiking on competitors!
Earning: See what the market has to say on Scribe Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Scribe Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Scribe Therapeutics
Scribe Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Scribe Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Scribe Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Scribe Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Scribe Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Scribe Therapeutics
Compare insights from companies similar to Scribe Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Scribe Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Scribe Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Scribe Therapeutics.
Scribe Therapeutics financials insights
Gather financial insights about Scribe Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$20M
2021
Series B
$100M
Scribe Therapeutics Tech Stack
A closer look at the technologies used by Scribe Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Person-Based
Medical Research, Clinical Operations
Person-Based
Medical Research, Clinical Operations
Person-Based
Research & Development, Pharmaceuticals
Scribe Therapeutics News & Media
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe to unveil latest preclinical data on proprietary CRISPR epigenetic silencing technology for LDL-C lowering at the 2025 EAS CongressScribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
ALAMEDA, Calif.--(BUSINESS WIRE)-- #ALS--Scribe presents data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering conferenceScribe Therapeutics to Participate in Upcoming Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics to participate in upcoming conferencesScribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves milestone for in vivo program in collaboration with Sanofi
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Scribe Therapeutics
Sign Up For FreeTo access detailed company insights
Scribe Therapeutics is focused on revolutionizing medicine through the development of CRISPR-based therapeutics aimed at transforming individuals' lifetime risk for diseases. Their innovative approach emphasizes preventative and accessible genetic medicine, targeting prevalent health issues such as cardiometabolic diseases. The company collaborates... Read More
